Korea Research Institute of Chemical Technology

Hanlim Pharmaceutical Co., Ltd.

Catholic University Industry Academic Cooperation Foundation

Yun-Seok Cho

Geun-Hyeog Lee

Sung-Eun Yoo

Choun-Ki Joo

Jin-Ha Park

Jun-Sub Choi

Mi-Jung Kim

Kyu-Yang Yi

Jee-Hee Suh

Dong-Yeop Shin

Mi-Jin O

Hye-Sung Lee

Jae-Sik Yang

Nack-Jeong Kim

Hu-Seong Kim

Kyung-Joon Kim

The present invention provides an eye drop formulation in the form of a solution, comprising (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof; propylene glycol as a stabilizing agent; and a pH controlling agent in an aqueous medium, wherein the eye drop formulation has a pH ranging from 4.0 to 5.0. The eye drop formulation of the present invention can contain (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof in a high concentration; and has an excellent stability. In addition, the pharmaceutical product for preventing or treating macular degeneration according to the present invention can be stored for extended periods.

Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof

The present invention provides a pharmaceutical composition for preventing or treating macular degeneration, which comprises benzopyran derivatives substituted with secondary amines including imidazole or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition of the present invention may be used in the form of eye drops.

Pharmaceutical composition for preventing or treating macular degeneration

Growing community of inventors

Suwon-si, South Korea

Yun-Seok Cho